Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 106,477 shares, a decline of 44.4% from the September 15th total of 191,429 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 359 shares, the days-to-cover ratio is presently 296.6 days.
Genmab A/S Stock Performance
OTCMKTS:GNMSF remained flat at $367.00 on Thursday. The stock has a market capitalization of $22.60 billion, a price-to-earnings ratio of 28.78 and a beta of 0.75. Genmab A/S has a 52-week low of $232.34 and a 52-week high of $396.97. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm’s fifty day moving average price is $339.77 and its two-hundred day moving average price is $293.22.
Genmab A/S Company Profile
Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.
Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies.
See Also
- Five stocks we like better than Genmab A/S
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
